Pharmacokinetics and Bioequivalence of Florfenicol Oral Solution Formulations (Flonicol® and Veterin®10%) in Broiler Chickens

Ehab A H Abu-Basha1, Ronette Gehring2*, Ahmad F Al-Shunnaq1 and Saad M Gharaibeh1

1Department of Veterinary Basic Medical Sciences, Faculty of Veterinary Medicine, Jordan University of Science and Technology, Irbid, Jordan
2Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, Kansas, USA
3Department of Pathology and Animal Health, Faculty of Veterinary Medicine, Jordan University of Science and Technology, Irbid, Jordan

Abstract

A pharmacokinetic and bioequivalence evaluation of two florfenicol oral solutions was carried out in 28 healthy broiler chickens after oral administration of a single dose of 20 mg/kg bw, according to a randomized, parallel experimental design. The two formulations were: Flonicol® (Mobedco, Jordan) as a test product and Veterin®10% (Centrevet, Chile) as a reference product. The pharmacokinetic analysis was performed using non-compartmental analysis based on statistical moment theory with the help of a commercially available software program (WinNonlin®, Pharsight Corp., Cary, NC, USA). There were no significant differences in the Cmax (9.02 ± 0.68, 9.20 ± 0.77 μg/ml), tmax (1.02 ± 0.13, 1.05 ± 0.30 h), t1/2β (1.41 ± 0.06, 1.35 ± 0.05 h), AUC0-12h (26.45 ± 1.33, 26.06 ± 1.20 μg.h/ml), AUC0-12h/F (26.61 ± 1.33, 26.26 ± 1.21 μg.h/ml), AUMC (71.78 ± 4.65, 69.98 ± 8.80 μg.h/ml), MRT (2.72 ± 0.18, 2.62 ± 0.27 h), Cl/F (12.82 ± 0.63, 12.96 ± 0.60 ml/min/kg) and Vdz/F (1.55 ± 0.08, 1.51 ± 0.08 l/kg) between Flonicol® and Veterin®10%, respectively. The 90% confidence interval for test: reference ratio of the AUC0-12h (91.86-111. 67 μg.h/ml), AUC0-12h/F (91.77-111.57 μg.h/ml) and Cmax (82.36-118.54 μg/ml) were within the European Agency for Evaluation of Medicinal Product (EMEA) and the US Food and Drug Administration (FDA) bioequivalence acceptable range (80%–125%). In conclusion, Flonicol® was found to be bioequivalent to Veterin®10% and can be used as interchangeable therapeutic agents in veterinary practice.

Keywords: Pharmacokinetics; Bioequivalence; Florfenicol; Chicken; High-pressure liquid chromatography

Abbreviations: HPLC – High-Performance Liquid Chromatography; LOQ – Limit of Quantification; LOD – Limit of Detection; AUC – Area under the concentration curve; AUMC – Area under the first moment curve; MRT – Mean Residence Time; Vd/F – Apparent volume of distribution corrected for unknown bioavailability; k10 – Elimination rate constant; t1/2β – Elimination half-life; Cl/F – Total body clearance corrected for unknown bioavailability; Cmax – Maximum measured plasma drug concentration is measured; tmax – Time at which maximum plasma drug concentration; MIC – Minimum Inhibitory Concentration; ANOVA – Analysis of Variance

Introduction

Florfenicol is a broad-spectrum bacteriostatic antibacterial that belongs to amphenicol family, with a wide range of activity against different types of Gram-negative and Gram-positive organisms including: Mannheimia haemolytica, Pasteurella multocida, Haemophilus somnus, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Salmonella typhi, Shigella dysenteriae and Staphylococcus aureus [1-3]. In addition, florfenicol is active at lower concentrations than its structural analogues, thiampenicol and chloramphenicol, against a number of bacterial pathogens and against many chloramphenicol or thiampenicol-resistant strains [4,5]. Florfenicol is approved in the European Union for use in cattle, sheep, pigs and chickens [6,7].

The efficacy of florfenicol has been demonstrated against many diseases of domestic animals [8-14]. However, to date, studies on the efficacy of florfenicol using pharmacokinetic/pharmacodynamic (PK/ PD) approaches have not been carried out in poultry. Nevertheless, the pharmacokinetics and bioavailability of florfenicol have been investigated in broiler chickens [15-17], turkeys [7] and ducks [18]. Most of these studies used the same original preparation of florfenicol. There is therefore little information available regarding the differences between formulations of florfenicol used in poultry.

Due to its advantages related to safety and efficacy over thiamphenicol and chloramphenicol, many florfenicol commercial preparations have been approved and employed in several countries for the treatment of serious gastrointestinal and respiratory bacterial infections in poultry and other farm animals [7,11,17]. In order to optimize the clinical outcome and to minimize the development of bacterial resistance, the copied pharmaceutical preparations must be bioequivalent to the innovator product [19,20]. These issues have become an on-going subject of concern within the European Community and the United States of America for registering new and generic drug products [19,21-23].

The aim of the present study was to evaluate the bioequivalence and comparative disposition kinetics of florfenicol following administration as one of two oral solutions; Flonicol® (Mobedco, Jordan) as a test product and Veterin®10% (Centrevet, Chile) as a reference product.

Materials and Methods

Drugs

Test product: Florfenicol®—Florfenicol, 10% oral solution, The
Ethyl acetate was added to the tubes then the mixture vortexed for 30 seconds and centrifuged for 5 min at 1000xg. The organic layer (ethyl acetate) was harvested and dried by heating at 60°C for 15 min. After evaporation, each residue was reconstituted in 250 μl of mobile phase and 100 μl was injected into the HPLC system.

**Calibration curve**

A standard calibration curve was prepared by adding 20 μl of florfenicol (1 mg/ml) to 980 μl antibacterial-free chicken plasma. This was further diluted into antibacterial-free chicken plasma to produce standards of 0.05, 0.1, 0.5, 1, 2, 5, 10 and 20 μg/ml. Standard solutions were extracted and analyzed using the same procedure as the unknown samples. Calibration curves were obtained by calculating the ratios of the area of florfenicol to that of chloramphenicol and plotting them against the corresponding concentration of florfenicol spiked in chicken plasma. The areas under the peaks were determined by integration using the software program Class-vp (Shimadzu, Japan).

**Validation procedure**

A complete validation of the analytical procedure that used for extraction and quantification of florfenicol was performed before analysis of experimental samples from the bioequivalence trials. Linearity, accuracy, precision, recovery and sensitivity were assessed. Two standard calibration curves with 7 concentrations (0.025, 0.05, 0.1, 0.5, 1, 2, 5 and 20 μg/ml) and 6 sets of quality control samples (0.3, 3 and 7 μg/ml) were prepared and analyzed daily for 3 consecutive days. The standard curves were linear over the range of 0.05 – 20 μg/ml (r²>0.9996). The calculated limit of detection (LOD) and the limit of quantification (LOQ) were 0.025 and 0.05 μg/ml based on a signal-to-noise ratio of 3:1 and 6:1, respectively. The mean analytical recovery percentage of florfenicol in plasma was ranged from 97.5 to 99.7 %. The inter- and intra-day assay coefficients of variation ranged from 1.5 to 6.33 %. The accuracy values ranged from 98.4 to 102.8%.

**Pharmacokinetic and statistical analysis**

The pharmacokinetic analysis of the data was performed using non-compartmental methods based on statistical moment theory as previously described [26], using the commercially available software (Win Nonlin®, Pharsight Corporation, Cary, NC, US). The calculated parameters were: area under plasma concentration-time curve (AUC) and area under the first moment curve (AUMC), using the linear trapezoidal method; mean residence time (MRT), where MRT= AUMC/AUC; volume of distribution (Vd/F), where Vd = dose/AUC; elimination rate constant (kₑ), which is the slope of the terminal log-linear portion of the plasma concentration-time profile, determined by least squares regression; AUC and AUMC extrapolated to infinity, by adding the ratio C∞/kₑ; elimination half-life (t½ₑ), where t½ₑ = 0.693/ kₑ; total body clearance (Cl/F), where Cl = dose/AUC. The maximum concentration (Cₘₐₓ), the corresponding peak time (tₘₐₓ) were determined by inspection of the individual drug plasma concentration-time profiles.

Differences between the pharmacokinetic parameters of the two tested formulations were evaluated by one-way analysis of variance (ANOVA) using the commercially available software package (SPSS Inc., version 10.0, Chicago, IL, USA). Data are reported as mean ± SE. The differences were considered significant when P<0.05. AUC₀⁻∞, AUC₀⁻t, AUC₀⁻∞, AUC₀⁻t and Cₘₐₓ were considered to be the primary variables for
bioequivalence testing. The 90% CI for the ratio of test/reference (T/R) was calculated using WinNonlin® (Version 5.2, Pharsight Corporation, Cary, NC, USA).

Results

All tested chickens used in the present study were clinically healthy throughout the experimental period. Florfenicol (Flonicol® and Veterin®10%) was well tolerated by all chickens. Unexpected incidents that could have influenced the outcome of the study did not occur. The concentrations of florfenicol in chicken plasma were determined up to 12h and were not detected in all chickens 24h post single oral administration of both products. The mean concentration–time profile for florfenicol oral solutions is shown in Table 1 and Figure 1. The mean plasma concentrations (µg/ml) of florfenicol (Flonicol®) and Veterin®10% were 26.45 ± 1.33 and 26.06 ± 1.20 µg.h/ml, 26.61 ± 1.33 and 26.26 ± 1.21 µg.h/ml, 9.02 ± 0.68 and 9.20 ± 0.77 µg/ml, respectively.

The results of the test for bioequivalence are shown in Table 3. The

<table>
<thead>
<tr>
<th>Time post-administration (h)</th>
<th>Flonicol® (Test)</th>
<th>Veterin®10% (Reference)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.166</td>
<td>2.24±0.50</td>
<td>2.11±0.57</td>
</tr>
<tr>
<td>0.33</td>
<td>4.42±0.96</td>
<td>5.89±1.12</td>
</tr>
<tr>
<td>0.5</td>
<td>6.80±1.16</td>
<td>7.95±1.24</td>
</tr>
<tr>
<td>0.75</td>
<td>7.02±1.10</td>
<td>7.92±1.16</td>
</tr>
<tr>
<td>1</td>
<td>7.38±0.90</td>
<td>7.43±0.86</td>
</tr>
<tr>
<td>1.5</td>
<td>7.02±0.65</td>
<td>6.42±0.44</td>
</tr>
<tr>
<td>2</td>
<td>5.99±0.55</td>
<td>5.38±0.37</td>
</tr>
<tr>
<td>4</td>
<td>2.54±0.21</td>
<td>2.51±0.38</td>
</tr>
<tr>
<td>6</td>
<td>1.02±0.17</td>
<td>0.99±0.19</td>
</tr>
<tr>
<td>8</td>
<td>0.53±0.18</td>
<td>0.34±0.08</td>
</tr>
<tr>
<td>10</td>
<td>0.13±0.03</td>
<td>0.14±0.02</td>
</tr>
<tr>
<td>12</td>
<td>0.08±0.01</td>
<td>0.10±0.02</td>
</tr>
</tbody>
</table>

Table 1: Mean plasma concentrations (µg/ml) of florfenicol (Flonicol® and Veterin®10%) in broiler chickens after a single oral dose of 20mg/kg bw. Values are mean ± SE (n=14).

Two pharmaceutical formulations are bioequivalent when 90% CI for the ratio of Cmax, AUC0-12h, and AUC0-∞ between test and reference formulations fall between 80-125%.

Table 3: Bioequivalence between Flonicol® (test) and Veterin®10% (reference) formulations.

90% confidence interval of the ratios of the log-transformed values for AUC0-12h, AUC0-∞, and Cmax for the two formulations were within the acceptable bioequivalence range (80-125%).

Discussion

Florfenicol has been approved and become a valuable antibacterial in the treatment of serious bacterial infections in farm animals [16,27]. In poultry, florfenicol is used extensively for the treatment of respiratory and gastrointestinal bacterial infections, administered via drinking water [7,17,24]. It has been reported that florfenicol showed greater activity than chloramphenicol and thiampheicol, especially against Pasteurella, Salmonella, E. coli and Staphylococcus aureus [28]. Moreover, Florfenicol has superior pharmacological and pharmacokinetics features over some other antimicrobials used in chicken industry [18,29,30]. This drug is characterized by high bioavailability (F>80%), good tissue penetration and rapid elimination, which are important for the systemic treatment of domestic animals [7,15].

Several commercial local and international pharmaceutical preparations of florfenicol oral solution are currently available. In this respect, generic pharmaceutical preparations of florfenicol seeking approval to enter the market should demonstrate their ability to achieve Cmax and AUC values that are equivalent to that of the original preparation. Inability to maintain high enough concentrations for sufficient periods of time may lead to therapeutic failure and may encourage the proliferation of resistant micro-organisms [19,23].
In this study, the pharmacokinetics and bioequivalence of two oral florfenicol solutions (Flonicol® and Veterin®10%) were investigated in healthy broiler chickens at a dose rate of 20mg/kg bw according to the manufacturer’s recommendations. In addition to the determination of the bioequivalence of both formulations, the results of the present experiment may contribute to the further understanding of the florfenicol plasma disposition kinetics in broiler chickens.

After a single oral administration of Flonicol® and Veterin®10% (20 mg/kg bw) to broiler chickens, both formulations were rapidly absorbed from the gastrointestinal tract and florfenicol was measurable at the first sampling time (10 min) in all chickens. The C_{max} was 9.02 ± 0.68 and 9.20 ± 0.77 μg/ml achieved at 01.02 ± 0.13 and 01.05 ± 0.30 (t_{max}) for Flonicol® and Veterin®10%, respectively. The C_{max} obtained in the present study were similar to those reported previously in chickens at a dose level of 20mg/kg bw (10.23 ± 1.67 μg/ml) [31], higher than those reported in chickens at a dose level of 30 mg/kg bw (5.82 ± 2.43 and 3.20 ± 0.20 μg/ml) [15,24] similar to those reported in E. coli infected broiler chickens (7.9 ± 3.00 μg/ml) [17] and lower than those reported in turkeys (12.25 ± 2.62 μg/ml) [7]. The observed t_{max} was similar to those reported in healthy broiler chickens (1.05 ± 0.07h and 1.35 ± 0.43h) [15,16] and E. coli infected broiler chickens (1.1 ± 0.43h) [5] but shorter than those reported in turkeys (2.0 ± 1.22h) [7].

The lowest concentration of antimicrobials, which inhibits the growth of the target pathogen, is referred to the minimum inhibitory concentration (MIC) [32]. Florfenicol is considered as a bacteriostatic antibiotic whereby the efficacy is closely correlated with concentrations maintained above the MIC for a longer proportion of the interdosing interval (T > MIC) [33]. To our knowledge, the MICs of florfenicol for bacterial isolates from poultry have not yet been determined, and it is warranted for future study. In the current study, florfenicol plasma concentration was maintained above 0.1 μg/ml for 12h post drug administration for both products. Therefore, it is likely that florfenicol will need to be given twice a day at a dosage of 20 mg/kg bw to maintain therapeutic concentrations or continued in water 3-5 days.

The elimination half-life (t_{1/2}) after oral administration of Flonicol® and Veterin®10% was 1.41 ± 0.06 and 1.35 ± 0.05h, respectively. The t_{1/2} was similar to those data reported in chickens (1.78 ± 0.19) [15] and E.coli infected broiler chickens (1.73 ± 0.25h) [17] and shorter than those reported in turkeys (3.76h) [7] and chickens in other studies (8.34 +/- 0.64h and 2.25 ± 0.53h) [13,31]. Differences between studies in chickens could be attributable to differences in the pharmacokinetic analysis (fitting to 1- versus 2-compartment models versus non-compartmental models).

This bioequivalence study was carried out in healthy broiler chicken under controlled conditions using a parallel design. The 90% confidence interval for the mean ratio of AUC(0–12h), AUC(0–∞) and C_{max} (91.86-111.67, 91.77-111.57 and 82.36-118.54%, respectively) were within the European Agency for Evaluation of Medicinal Product (EMEA) and the US Food and Drug Administration (US-FDA) bioequivalence acceptance range of 80-125% (EMEA, 2006; FDA, 2006). Moreover, the average mean of C_{max}, t_{max}, AUC(0–12h), AUC(0–∞), C_{t/2}, CI, MRT, Vd, and AUMC were found to be very close with no significant difference between the two formulations. Based on the above pharmacokinetic and statistical results calculated in the current study, we concluded that Florfenicol®, manufactured by Mobedco-Jordan, is bioequivalent to Veterin®10%, manufactured by Centrovet-Chile, and both products can be used as interchangeable drug in veterinary practice.

### Acknowledgments

This study was funded by Business & Export Development Project for Jordanian Enterprises ( Tatweer) and USAID.

### References


